ASLAN’s Pan-HER Inhibitor Shows Positive Data In Gastric Cancer PhII Study
In Asia, a Phase II study conducted at Seoul National University Hospital, South Korea showed positive data in heavily pretreated people with recurrent/metastatic gastric carcinoma whose tumors were HER2 amplified or coexpressing EGFR and HER2 …
